REVIEW PAPER
Management of gallstone disease in children
1
Children’s Memorial Health Institute, Warsaw, Poland
Submission date: 2023-02-21
Final revision date: 2023-03-29
Acceptance date: 2023-04-02
Publication date: 2023-09-29
Corresponding author
Anna Orłowska
Anna Orłowska, MD, PhD, Children’s Memorial Health Institute, Warsaw, Poland
Anna Orłowska, MD, PhD, Children’s Memorial Health Institute, Warsaw, Poland
Pediatr Pol 2023;98(3):229-235
KEYWORDS
TOPICS
ABSTRACT
In recent years an increase in incidence of cholelithiasis in children has been observed. Among the various factors predisposing to the occurrence of cholelithiasis, some are modifiable and some are non-modifiable (including 25% of gallstones caused by genetic factors). One of the factors predisposing to the occurrence of cholelithiasis is obesity. The article describes the methods of prevention, diagnosis and treatment of uncomplicated and complicated cholelithiasis in children. Attention was paid to the new guidelines for the use of ursodeoxycholic acid in gallstone disease, as well as the molecular basis and research progress that has been made in this field.
REFERENCES (51)
1.
Di Ciaula A, Portincasa P. Recent advances in understanding and managing cholesterol gallstones. F1000Res. 2018; 24: F1000.
2.
Tuna Kirsaclioglu C, Çuhacı Çakır B, Bayram G, et al. Risk factors, complications and outcome of cholelithiasis in children: a retrospective, single-centre review. J Paediatr Child Health 2016; 52: 944-949.
3.
Mehta S, Lopez ME, Chumpitazi BP, et al. Clinical characteristics and risk factors for symptomatic pediatric gallbladder disease. Pediatrics 2012; 129: e82-8.
4.
Frybova B, Drabek J, Lochmannova J, et al. Cholelithiasis and choledocholithiasis in children; risk factors for development. PLoS One 2018; 13: e0196475.
5.
Iwańczak F, Stawarski A, Iwańczak B, et al. Czynniki ryzyka i objawy kliniczne kamicy żółciowej u dzieci. Pediatr Pol 2004; 79: 520-528.
6.
Cortés VA, Barrera F, Nervi F. Pathophysiological connections between gallstone disease, insulin resistance, and obesity. Obes Rev 2020: 21: e12983.
7.
Weikert C, Weikert S, Schulze MB, et al. Presence of gallstones or kidney stones and risk of type 2 diabetes. Am J Epidemiol 2010; 171: 447-454.
8.
Sun H, Warren J, Yip J, et al. Factors influencing gallstone formation: a review of the literature. Biomolecules 2022; 12: 550.
9.
Bogue CO, Murphy AJ, Gerstle JT, et al. Risk factors, complications, and outcomes of gallstones in children: a single-center review. J Pediatr Gastroenterol Nutr 2010; 50: 303-308.
10.
Jafari SH, Haseli S, Kaffashan S, Saeedi-Moghadam M, Iran- pour P, Zeinali-Rafsanjani B. Assessment of the hallmarks of Wilson disease in CT scan imaging. J Med Imaging Radiat Sci 2020; 51: 145-153.
11.
Alvarenga LR, Sandy NS, Gomez GS, Hessel G, DETommaso AMA, Bellomo-Brandão M. Symptomatic cholelithiasis as the presentation of pediatric primary sclerosing cholangitis – case series and literature review. Arq Gastroenterol 2021; 58: 227-233.
12.
Katsika D, Grjibovski A, Einarsson C, et al. Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. Hepatology 2005; 41: 1138-1143.
13.
Krawczyk M, Niewiadomska O, Jankowska I, et al. Common variant p.D19H of the hepatobiliary sterol transporter ABCG8 increases the risk of gallstones in children. Liver Int 2022; 42: 1585-1592.
14.
Pogorelić Z, Aralica M, Jukić M, et al. Gallbladder disease in children: a 20-year single-center experience.. Indian Pediatr 2019; 56: 384-386.
15.
Kiewiet JJS, Leeuwenburgh MMN, Bipat S, et al. A systemic review and meta-analysis of diagnostic performance of imaging in acute cholecystitis. Radiology 2012; 264: 708-720.
16.
Bhaumik K. Asymptomatic cholelithiasis in children: management dilemma. J Indian Assoc Pediatr Surg 2021; 26: 228-233.
17.
Buch S, Schafmayer C, Völzke H, et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet 2007; 39: 995-999.
18.
Krawczyk M, Lütjohann D, Schirin-Sokhan R, et al. Phytosterol and cholesterol precursor levels indicate increased cholesterol excretion and biosynthesis in gallstone disease. Hepatology 2012; 55: 1507-1517.
19.
Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-1204.
20.
Lee MH, Lu K, Hazard S, et al. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet 2001; 27: 79-83.
21.
Davis HR, Zhu LJ, Hoos LM, et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem 2004; 279: 33586-33592.
22.
Yu L, Hammer RE, Li-Hawkins J, et al. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci U S A 2002; 99: 16237-16242.
23.
Dong C, Condat B, Picon-Coste M, et al. Low-phospholipid-associated cholelithiasis syndrome: prevalence, clinical features, and comorbidities. JHEP Rep 2021; 3: 100201.
24.
Schatz SB, Jüngst C, Keitel-Anselmo V, et al. Phenotypic spectrum and diagnostic pitfalls of ABCB4 deficiency depending on age of onset. Hepatol Commun 2018; 2: 504-514.
25.
Renner O, Harsch S, Schaeffeler E, et al. A variant of the SLC10A2 gene encoding the apical sodium-dependent bile acid transporter is a risk factor for gallstone disease. PLoS One. 2009; 4: e7321.
26.
Dixit M, Choudhuri G, Saxena R, et al. Association of apolipoprotein A1-C3 gene cluster polymorphisms with gallstone disease. Can J Gastroenterol 2007; 21: 569-575.
27.
Wang HH, Wang DQ. Reduced susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine. Hepatology 2005; 42: 894-904.
28.
Portincasa P, van Erpecum KJ, van De Meeberg PC, et al. Apolipoprotein E4 genotype and gallbladder motility influence speed of gallstone clearance and risk of recurrence after extracorporeal shock-wave lithotripsy. Hepatology 1996; 24: 580-587.
29.
Juvonen T, Kervinen K, Kairaluoma MI, et al. Gallstone cholesterol content is related to apolipoprotein E polymorphism. Gastroenterology 1993; 104: 1806-1813.
30.
Mella JG, Schirin-Sokhan R, Rigotti A, et al. Genetic evidence that apolipoprotein E4 is not a relevant susceptibility factor for cholelithiasis in two high-risk populations. J Lipid Res 2007; 48: 1378-1385.
31.
Lin JP, Hanis CL, Boerwinkle E. Genetic epidemiology of gallbladder disease in Mexican-Americans and cholesterol 7α-hydroxylase gene variation. Am J Hum Genet 1994; 55: A48.
32.
Li T, Owsley E, Matozel M, et al. Transgenic expression of cholesterol 7alpha-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology 2010; 52: 678-690.
33.
Wang DQ, Schmitz F, Kopin AS, et al. Targeted disruption of the murine cholecystokinin-1 receptor promotes intestinal cholesterol absorption and susceptibility to cholesterol cholelithiasis. J Clin Invest 2004; 114: 521-528.
34.
Andreotti G, Chen J, Gao YT, et al. Polymorphisms of genes in the lipid metabolism pathway and risk of biliary tract cancers and stones: a population-based case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2008; 17: 525-534.
35.
European Association for the Study of the Liver: EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. J Hepatol 2016; 65: 146-181.
36.
Kiriyama S et al Tokyo Guidelines Revision Committee. New diagnostic criteria and severity assessment of acute cholangitis in revised Tokyo Guidelines. J Hepatobiliary Pancreat Sci 2012; 19: 548-556.
37.
Jeong SH, Lee HS. Hepatitis A: clinical manifestations and management. Intervirology 2010; 53: 15-19.
38.
Imran M, Khan SA, Malik MI. Spectrum of acute, recurrent and chronic pancreatitis in children. J Pak Med Assoc 2020; 70: 2412-2415.
39.
Sellers ZM, MacIsaac D, Yu H, et al. Nationwide trends in acute and chronic pancreatitis among privately insured children and non- elderly adults in the United States, 2007–2014. Gastroenterology 2018; 155: 469-478.e1.
40.
Chamorro CC, Arteaga P, Paredes C, et al. Cholelithiasis and associated complications in pediatric patients. Cir Pediatr 2020; 33: 172-176.
41.
Leitzmann MF, Giovannucci EL, Rimm EB, et al. The relation of physical activity to risk for symptomatic gallstone disease in men. Ann Intern Med 1998; 128: 417-425.
42.
Di Ciaula A, Garruti G, Frühbeck G, et al. The role of diet in the pathogenesis of cholesterol gallstones. Curr. Med Chem 2019; 26: 3620-3638.
43.
Miller K, Hell E, Lang B, Lengauer E. Gallstone formation prophylaxis after gastric restrictive procedures for weight loss: a randomized double-blind placebo-controlled trial. Ann Surg 2003; 238: 697-702.
44.
Rosmorduc O, Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene. Orphanet J Rare Dis 2007; 2: 29.
45.
Petroni ML, Jazrawi RP, Goggin PM, et al. Characteristics of recurrent gallstones following non-surgical treatment: implications for retreatment. Eur J Gastroenterol Hepatol 1991; 3: 473-478.
46.
Sackmann M, Pauletzki J, Aydemir U, et al. Efficacy and safety of ursodeoxycholic acid for dissolution of gallstone fragments: comparison with the combination of ursodeoxycholic acid and chenodeoxycholic acid. Hepatology 1991; 14: 1136-1141.
47.
Della Corte C, Falchetti D, Nebbia G, et al. Management of cholelithiasis in Italian children: a national multicenter study. World J Gastroenterol 2008; 14: 1383-1388.
48.
Morris-Stiff G, Sarvepalli S, Hu B, et al. Natural history of asymptomatic gallstones: a longitudinal study and prediction model. Clin Gastroenterol Hepatol 2023; 21: 319-327.e4.
49.
Fraquelli M, Casazza G, Conte D, et al. Non-steroid anti-inflammatory drugs for biliary colic. CDSR 2016; 9: CD006390.
50.
Venneman NG, Besselink MG, Keulemans YC, et al. Ursodeoxycholic acid exerts no beneficial effect in patients with symptomatic gallstones awaiting cholecystectomy. Hepatology 2006; 43: 1276-1283.
51.
Westphal JF, Brogard JM. Biliary tract infections: a guide to drug treatment. Drugs 1999; 57: 81-91.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
